A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)
A phase 3 trial of Izalontamab brengitecan, Topotecan in small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
Overview
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) is a phase 3 interventional study registered as NCT06500026 by Sichuan Baili Pharmaceutical Co., Ltd., with 722 participants enrolled, started 2024-08-07 and due to reach its primary completion in 2026-12. Interventions recorded: BL-B01D1, Topotecan. Conditions listed: Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer.
- TrialA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer.
- TrialA Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer.
- TrialA Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer.
- TrialA Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer.
- TrialA Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer.
- TrialA Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metas
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer.
- TrialA Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-s
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer.